Navigation Links
Medivir Announces TMC435 in an Expanded Clinical Collaboration
Date:4/18/2012

study comparing TMC435 versus telaprevir, each in combination with Pegylated Interferon α-2a (PegINF) and ribavirin (RBV), in hepatitis C genotype-1 infected patients who were null or partial responders to prior PegINF/RBV therapy
  • TMC435-C3011 is an open label, single arm phase III trial to explore the efficacy, safety and tolerability of TMC435 150 mg once daily, in combination with PegIFN/RBV in 100 treatment naïve or treatment experienced, hepatitis C genotype-4 infected patients  

  • For additional information from these studies, please see http://www.medivir.com and http://www.clinicaltrials.gov

    About Hepatitis C

    Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The World Health Organization estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost three million people in the United States are chronically infected with HCV.

    About Medivir

    Medivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is TM
    '/>"/>

    SOURCE Medivir
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Medivir: R&D Day
    2. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
    3. CardioInsight Announces Appointment of Jim Bullock as Chairman of the Board of Directors
    4. WaferGen Bio-systems Announces Open Format qPCR Platform and Strategic Realignment
    5. Custom Spine Announces 510K Clearance for Securis Cannulated Screw System
    6. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
    7. Islet Sciences Announces Receipt of $2.1 Million in Grant Support of Technology
    8. ADVENTRX Announces Establishment of Regulatory Advisory Board
    9. Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
    10. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
    11. GenVec Announces Research on Improved Vaccine Vectors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... , Aug. 20, 2014 Clintrax Global, ... located in Raleigh, NC , ... as Vice President of Administration. ... oversee all corporate processes, including their alignment with ... Global, Brad worked as an HR executive, specializing ...
    (Date:8/20/2014)... licensed to biotechnology firms has revealed early bottlenecks ... roadblocks, the researchers suggest that better communication of ... lead to faster commercialization down the road. , ... in university laboratories and licensed to biotechnology firms. ... have a high failure rate. But a new ...
    (Date:8/20/2014)... have it that American Indians largely were wiped out ... and tuberculosis brought to the New World by European ... million people lived in the Americas shortly before Europeans ... by European diseases., But new research led by anthropological ... Krause of the University of Tubingen in Germany indicates ...
    (Date:8/20/2014)... chemists have succeeded in measuring vibrational motion of a ... reveals how vibration of a single molecule differs from ... study was performed at the University of California, Irvine, ... Jyvskyl works as a visiting fellow under professor Vartkess ... second team was lead by Professor Eric O. Potma. ...
    Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3Seeing a molecule breathe 2
    ... 22, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic ... that the company will be exhibiting at the 61st ... of Cardiology (ACC) in Chicago, March 24-27, Booth #15084. ... is the first and only multiple biomarker blood test ...
    ... The new Dynaflow Resolve System was developed in close ... demand for a simpler technology capable of complex perfusion ... perfusion system that enables novel experimental protocols by allowing ... type, and any compound. The new and improved system ...
    ... March 21, 2012 AtheroNova Inc. (OTCBB: AHRO), a ... compounds to regress atherosclerotic plaque, today announced that it ... development stage company, no revenues were recognized in the ... were $2,560,235 for 2011 compared to $2,679,435 in 2010. ...
    Cached Biology Technology:FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo 2Cellectricon Launches Dynaflow® Resolve System Enabling Novel Ion Channel Assays 2AtheroNova Releases 2011 Financial Results 2AtheroNova Releases 2011 Financial Results 3
    (Date:8/20/2014)... George E. Fox, a John and Rebecca Moores Professor ... was named a fellow in the International Society for the ... is one of four members two from the U.S., ... fellows in 2014. Fellows are elected every three years, and ... members from more than 20 countries, the ISSOL includes researchers ...
    (Date:8/20/2014)... a study of 158 pregnant teenagers in Rochester, NY, ... intentional consumption of ice, cornstarch, vacuum dust, baby powder ... Cornell study. , Moreover, such teens had significantly lower ... eat nonfood substances. , Pregnant teens, regardless of pica, ... lead to iron deficiency and anemia. Low iron in ...
    (Date:8/20/2014)... Cancer Institute (HCI) at the University of Utah have ... encodes BCR-ABL, the unregulated enzyme driving the blood cancer ... Society, nearly 6,000 new cases of CML will be ... tyrosine kinase inhibitors (TKIs), target BCR-ABL and are effective ... but control it in a way that allows patients ...
    Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Pica in pregnant teens linked to low iron 2Blueprint for next generation of chronic myeloid leukemia treatment 2
    ... A rose by any other name may smell as sweet, but ... is booted out of the grass family, where does it go? ... recently investigated the evolution of grasses, one of the most economic ... an early diverging grass genus, Anomochloa , and comparing it ...
    ... could determine the amount of carbon dioxide emitted from soils ... this week in Nature Geoscience . Researchers at ... Forestry & Environmental Studies have found that as global temperatures ... converting carbon in soil into carbon dioxide, which is a ...
    ... WEST LAFAYETTE, Ind. - Just months after the soybean ... a long-sought gene that controls the plant,s main stem ... types of soybean plants that will allow producers to ... Ma (Jen-Shin Ma), an assistant professor of agronomy, used ...
    Cached Biology News:What is a grass? 2Microbes contribute less to climate warming 2Gene discovery may lead to new varieties of soybean plants 2
    ... F2α isopropyl ester (15(R)-17-phenyl trinor PGF2α ... containing both a double bond at ... group at C-15. Similar to 15(S)-latanoprost, ... a potential impurity in most commercial ...
    ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
    ... Nop1p/Fibrillarin (monoclonal) Nop1p/Fibrillarin was ... of bakers yeast, Saccharomyces cerevisiae (accession ... for yeast viability and is localized ... of Nop1p is fibrillarin (accession P22087) ...
    ... bind specifically to Fc regions of many ... conjugates are commonly used as affinity adsorbents ... from serum, hybridoma ascites fluids, tissue culture ... are also commonly used to capture immune ...
    Biology Products: